MC 02306
Latest Information Update: 13 Jun 2001
Price :
$50 *
At a glance
- Originator Essential Therapeutics [CEASED]
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 13 Jun 2001 Discontinued-Preclinical for Bacterial infections in USA (Unknown route)
- 04 Aug 1998 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 02 Feb 1996 Preclinical development for Bacterial infections in USA (Unknown route)